TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+6.47%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.7B
AUM Growth
+$2.7B
(+4.7%)
Cap. Flow
-$36M
Cap. Flow
% of AUM
-1.33%
Top 10 Holdings %
Top 10 Hldgs %
44.18%
Holding
152
New
13
Increased
22
Reduced
27
Closed
8
Top Buys
| 1 |
Merck
MRK
|
$17.6M |
| 2 |
NVRO
NEVRO CORP.
NVRO
|
$14.5M |
| 3 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$14.1M |
| 4 |
Novartis
NVS
|
$12.5M |
| 5 |
Biogen
BIIB
|
$12.2M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$30.3M |
| 2 |
Molina Healthcare
MOH
|
$18.4M |
| 3 |
Thermo Fisher Scientific
TMO
|
$15.5M |
| 4 |
Pfizer
PFE
|
$11.3M |
| 5 |
Health Care Select Sector SPDR Fund
XLV
|
$10.5M |
Sector Composition
| 1 | Healthcare | 91.69% |
| 2 | Real Estate | 3.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Neurocrine Biosciences
NBIX
$13.5B
| $25.9M | 0.96% |
562,467
+116,393
| +26% | +$5.35M |
|
|
27
Thermo Fisher Scientific
TMO
$183B
| $24.3M | 0.9% |
139,120
-88,900
| -39% | -$15.5M |
|
28
Cencora
COR
$57.2B
| $24.1M | 0.89% |
254,887
-75,800
| -23% | -$7.17M |
|
29
iShares Biotechnology ETF
IBB
$5.68B
| $23.6M | 0.87% |
227,910
-6,000
| -3% | -$620K |
|
30
McKesson
MCK
$85.9B
| $23.5M | 0.87% |
142,800
+29,700
| +26% | +$4.89M |
|
31
Idexx Laboratories
IDXX
$50.7B
| $21.4M | 0.79% |
132,352
| – | – |
|
32
AstraZeneca
AZN
$255B
| $18.8M | 0.7% |
550,600
+86,800
| +19% | +$2.96M |
|
33
Puma Biotechnology
PBYI
$258M
| $17.7M | 0.66% |
202,537
-57,663
| -22% | -$5.04M |
|
34
SPDR S&P Biotech ETF
XBI
$5.29B
| $17.5M | 0.65% |
226,460
| – | – |
|
35
Sarepta Therapeutics
SRPT
$1.98B
| $17.2M | 0.64% |
511,600
| – | – |
|
36
GSK
GSK
$79.3B
| $15.5M | 0.57% |
287,200
| – | – |
|
37
Centene
CNC
$14.8B
| $15.4M | 0.57% |
385,200
+96,600
| +33% | +$3.86M |
|
38
Omega Healthcare
OHI
$12.5B
| $15.1M | 0.56% |
458,616
| – | – |
|
|
NVRO
39
DELISTED
NEVRO CORP.
NVRO
| $14.5M | 0.54% |
+194,621
| New | +$14.5M |
|
|
PVLA
40
Palvella Therapeutics, Inc. Common Stock
PVLA
$592M
| $14.4M | 0.53% |
35,470
-13,781
| -28% | -$5.58M |
|
|
CLVS
41
DELISTED
Clovis Oncology, Inc.
CLVS
| $14.1M | 0.52% |
+150,800
| New | +$14.1M |
|
42
Cigna
CI
$80.2B
| $14M | 0.52% |
83,900
| – | – |
|
43
Exelixis
EXEL
$9.95B
| $13.6M | 0.5% |
551,647
| – | – |
|
44
Sabra Healthcare REIT
SBRA
$4.56B
| $13.3M | 0.49% |
550,990
| – | – |
|
|
WELL.PRI
45
DELISTED
Welltower Inc.
WELL.PRI
| $13.3M | 0.49% |
200,000
| – | – |
|
|
DHC
46
Diversified Healthcare Trust
DHC
$903M
| $13.2M | 0.49% |
646,554
| – | – |
|
47
Zimmer Biomet
ZBH
$20.8B
| $13.1M | 0.49% |
105,369
| – | – |
|
48
Medical Properties Trust
MPW
$2.66B
| $13M | 0.48% |
1,007,717
| – | – |
|
49
Charles River Laboratories
CRL
$7.99B
| $12.9M | 0.48% |
127,100
| – | – |
|
|
PRTK
50
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $12.8M | 0.48% |
533,000
-229,581
| -30% | -$5.53M |
|